Abstract
This report provides a comprehensive analysis of the global COVID-19 vaccine market, tracking its significant growth trajectory through 2033. It examines key segments including vaccine types like mRNA and viral vectors, various routes of administration, and diverse age groups across major global regions. By evaluating competitive landscapes, technological advancements, and shifting market dynamics, the research offers stakeholders actionable intelligence on product development, pricing strategies, and emerging trends to navigate this evolving healthcare sector.
Related Questions
US$ 13.43 billion in 2024
9.80% (2026-2033)
product development, pricing strategies, global expansion initiatives
Summary
Market Overview
- Market Size (2024): US$ 13.43 billion
- Projected Market Size (2033): US$ 29.98 billion
- Compound Annual Growth Rate (CAGR): 9.80% during the forecast period 2026-2033
DataM Intelligence provides an in-depth analysis of the COVID-19 Vaccine Market, utilizing advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
Definition/Context: A COVID-19 Vaccine Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
Market Segmentation
By Infection Type
- SARS-CoV-2
- HCoVs
- Others
By Vaccine Type
- mRNA Vaccines
- Viral Vector Vaccines
- Inactivated Virus Vaccines
- Protein Subunit Vaccines
- Live Attenuated Vaccines
- Others
By Route of Administration
- Intramuscular
- Subcutaneous
- Oral
By Age Group
- Below 18 Years
- Above 18 Years
By End-User
- Hospitals
- Specialty Clinics
- Others
Regional Analysis
- North America: U.S., Canada, Mexico
- Europe: U.K., Italy, Germany, Russia, France, Spain, The Netherlands, and Rest of Europe
- Asia-Pacific: India, Japan, China, South Korea, Australia, Indonesia, and Rest of Asia Pacific
- South America: Colombia, Brazil, Argentina, and Rest of South America
- Middle East & Africa: Saudi Arabia, U.A.E., South Africa, and Rest of Middle East & Africa
Report Coverage and Scope
This report includes the following comprehensive analyses:
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends and development status.
- Competitive landscape analysis.
- Supply side analysis and demand side analysis.
- Year-on-year growth.
- Competitive benchmarking.
- Vendor identification.
- Customized regional/country reports as per request and country level analysis.
- Identification of potential and niche segments and regions exhibiting promising growth.
- Analysis of Market Size (historical and forecast).
- Total Addressable Market (TAM).
- Serviceable Available Market (SAM).
- Serviceable Obtainable Market (SOM).
- Market Growth and Market Dynamics.
- Technological Trends.
- Market Share.
- Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Research Methodology
Both primary and secondary data sources have been used in the global COVID-19 Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including:
- Governmental regulations.
- Market conditions.
- Competitive levels.
- Historical data.
- Market situation.
- Technological advancements.
- Upcoming developments in related businesses.
- Market volatility.
- Prospects, potential barriers, and challenges.
Table of Contents
1 Methodology and Scope
1.1 Research Methodology
1.2 Research Objective and Scope of the Report
2 Definition and Overview
3 Executive Summary
3.1 Snippet by Infection Type
3.2 Snippet by Vaccine Type
3.3 Snippet by Route of Administration
3.4 Snippet by Age Group
3.5 Snippet by End-User
3.6 Snippet by Region
4 Dynamics
4.1 Impacting Factors
4.1.1 Drivers
- 4.1.1.1 Government Support and Initiatives
- 4.1.1.2 XX
4.1.2 Restraints
- 4.1.2.1 Limited Manufacturing Capacity
4.1.3 Opportunity
4.1.4 Impact Analysis
5 Industry Analysis
5.1 Porter’s Five Force Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Patent Analysis
5.5 Regulatory Analysis
5.6 SWOT Analysis
5.7 Unmet Needs
6 By Infection Type
6.1 Introduction
6.1.1 Analysis and Y-o-Y Growth Analysis (%), By Infection Type
6.1.2 Market Attractiveness Index, By Infection Type
6.2 SARS-CoV-2*
6.2.1 Introduction
6.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3 HCoVs
6.4 Others
7 By Vaccine Type
7.1 Introduction
7.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
7.1.2 Market Attractiveness Index, By Vaccine Type
7.2 mRNA Vaccines*
7.2.1 Introduction
7.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3 Viral Vector Vaccines
7.4 Inactivated Virus Vaccines
7.5 Protein Subunit Vaccines
7.6 Live Attenuated Vaccines
7.7 Others
8 By Route of Administration
8.1 Introduction
8.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2 Market Attractiveness Index, By Route of Administration
8.2 Intramuscular*
8.2.1 Introduction
8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3 Subcutaneous
8.4 Oral
9 By Age Group
9.1 Introduction
9.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.1.2 Market Attractiveness Index, By Age Group
9.2 Below 18 Years*
9.2.1 Introduction
9.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3 Above 18 Years
10 By End-User
10.1 Introduction
10.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2 Market Attractiveness Index, By End-User
10.2 Hospitals *
10.2.1 Introduction
10.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3 Specialty Clinics
10.4 Others
11 By Region
11.1 Introduction
11.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2 Market Attractiveness Index, By Region
11.2 North America
11.2.1 Introduction
11.2.2 Key Region-Specific Dynamics
11.2.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
11.2.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
11.2.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.2.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.8.1 U.S
- 11.2.8.2 Canada
- 11.2.8.3 Mexico
11.3 Europe
11.3.1 Introduction
11.3.2 Key Region-Specific Dynamics
11.3.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
11.3.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
11.3.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.3.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.8.1 Germany
- 11.3.8.2 U.K
- 11.3.8.3 France
- 11.3.8.4 Spain
- 11.3.8.5 Italy
- 11.3.8.6 Rest of Europe
11.4 South America
11.4.1 Introduction
11.4.2 Key Region-Specific Dynamics
11.4.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
11.4.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
11.4.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.4.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.8.1 Brazil
- 11.4.8.2 Argentina
- 11.4.8.3 Rest of South America
11.5 Asia-Pacific
11.5.1 Introduction
11.5.2 Key Region-Specific Dynamics
11.5.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
11.5.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
11.5.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.5.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.8.1 China
- 11.5.8.2 India
- 11.5.8.3 Japan
- 11.5.8.4 South Korea
- 11.5.8.5 Rest of Asia-Pacific
11.6 Middle East and Africa
11.6.1 Introduction
11.6.2 Key Region-Specific Dynamics
11.6.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
11.6.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
11.6.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.6.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12 Competitive Landscape
12.1 Competitive Scenario
12.2 Market Positioning/Share Analysis
12.3 Mergers and Acquisitions Analysis
13 Company Profiles
13.1 Pfizer/BioNTech*
13.1.1 Company Overview
13.1.2 Product Portfolio
- 13.1.2.1 Product Description
- 13.1.2.2 Product Key Performance Indicators (KPIs)
- 13.1.2.3 Historic and Forecasted Product Sales
- 13.1.2.4 Product Sales Volume
13.1.3 Financial Overview
- 13.1.3.1 Company Revenue’s
- 13.1.3.2 Geographical Revenue Shares
- 13.1.3.3 Revenue Forecasts
13.1.4 Key Developments
- 13.1.4.1 Mergers & Acquisitions
- 13.1.4.2 Key Product Development Activities
- 13.1.4.3 Regulatory Approvals etc
13.1.5 SWOT Analysis
13.2 Moderna, Inc
13.3 AstraZeneca
13.4 Johnson & Johnson (Janssen Scientific Affairs, LLC)
13.5 SINOVAC
13.6 CanSino Biologics Inc
13.7 Novavax
13.8 Sanofi/GSK
13.9 Beijing Institute of Biological Products Co., Ltd
13.10 Serum Institute of India Pvt. Ltd
13.11 Gamaleya Research Institute (*LIST NOT EXHAUSTIVE)
14 Appendix
14.1 About Us and Services
14.2 Contact Us